The three major US stock indexes closed up the entire line, and the Dow rose 1.18%to 39069.11 points. The S & P 500 index rose 2.11%to 5087.03 points, a record high, and the NATO rose 2.96%to 16041.62 points.The Nasdaq Biotechnology Index rose 1.37%to 4455.98 points.
Global biotechnology giants in ingredients stocks rose 13.53%, Aliram Pharmaceuticals rose more than 5%, Bymalin Pharmaceutical and Regenerative Pharmaceuticals rose more than 1%, to Zhihui, Anjin, , etc.Illumina and Geely Germany scientifically closed down.
As of the afternoon closing of February 23, 2024, the Nasda Index Biotechnology ETF (513290) closed up 1.22%, the latest price was 1.16 yuan, and the turnover in the morning reached 47.1837 million yuan.
In terms of capital inflows, the Nasda Biotechnology ETF has a net inflow of funds in 9 days in the nearly 17 trading days, with a total of 103 million yuan, a daily net inflow of 60.34 million yuan.
Data show that leverage funds are continuously layout.The latest financing purchase amount of the NATF biotechnology ETF reached 3.25 million yuan, and the latest financing balance reached 16.0431 million yuan.
Yesterday, Modner announced the fourth quarter of the fiscal year in fiscal year in fiscal.It was $ 1.465 billion.The annual revenue was US $ 6.848 billion, and the same period last year was $ 19.263 billion.
Traffic Bank International believes that the pharmaceutical industry has a significant rebound, but the current valuation is still in the bottom interval, and the sector is still highly elastic in the short term.In addition, with the continuous capacity of the sales of Nutrpo peptides and Smegugu, the stock price of Lili and Nond Norders reached a new high. During the Spring Festival, the success of the star weight loss, stacking the GCGR/GLP-1R dual target innovative drugThe recent NDA has been accepted by Masidin, which once again attracted investors attention to the weight loss pill market.Entering March-April, it is recommended to pay attention to the performance/first quarterly report of pharmaceutical companies. The sales of innovative drugs are expected to restore the rhythm and have a certain possibility of supermarket expectations. As the investment emotion of the sector stabilizes, the stock price is expected to continue to repair.
Nasda refers to biotechnology ETF (513290), off -site connection (category A: 017894; Class C: 017895; Huitian Funasdaq Biotechnology ETF initial connection (QDII)US dollar exchange: 017951; Huitian Funasdaq Biotechnology ETF initial connection (QDII) US dollar cash: 017952).
